JP2012528891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528891A5 JP2012528891A5 JP2012514183A JP2012514183A JP2012528891A5 JP 2012528891 A5 JP2012528891 A5 JP 2012528891A5 JP 2012514183 A JP2012514183 A JP 2012514183A JP 2012514183 A JP2012514183 A JP 2012514183A JP 2012528891 A5 JP2012528891 A5 JP 2012528891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- item
- composition
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 210000003454 tympanic membrane Anatomy 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- 230000005540 biological transmission Effects 0.000 claims description 8
- 102000002689 Toll-like receptor Human genes 0.000 claims description 6
- 108020000411 Toll-like receptor Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 5
- 206010033078 Otitis media Diseases 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 4
- 208000005141 Otitis Diseases 0.000 claims description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
- 210000000883 ear external Anatomy 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 210000003928 nasal cavity Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- -1 vapor Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 150000008574 D-amino acids Chemical group 0.000 description 18
- 201000004624 Dermatitis Diseases 0.000 description 14
- 201000004681 Psoriasis Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000003027 ear inner Anatomy 0.000 description 5
- 210000000959 ear middle Anatomy 0.000 description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
- 206010012441 Dermatitis bullous Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010028703 Nail psoriasis Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037575 Pustular psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000025255 bacterial arthritis Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 208000002849 chondrocalcinosis Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000013460 sweaty Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18445509P | 2009-06-05 | 2009-06-05 | |
| US18443809P | 2009-06-05 | 2009-06-05 | |
| US61/184,438 | 2009-06-05 | ||
| US61/184,455 | 2009-06-05 | ||
| US22073809P | 2009-06-26 | 2009-06-26 | |
| US22074509P | 2009-06-26 | 2009-06-26 | |
| US61/220,745 | 2009-06-26 | ||
| US61/220,738 | 2009-06-26 | ||
| US25636409P | 2009-10-30 | 2009-10-30 | |
| US61/256,364 | 2009-10-30 | ||
| PCT/US2010/037443 WO2010141845A2 (en) | 2009-06-05 | 2010-06-04 | Immunoregulatory peptides and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528891A JP2012528891A (ja) | 2012-11-15 |
| JP2012528891A5 true JP2012528891A5 (enExample) | 2013-07-18 |
| JP5797191B2 JP5797191B2 (ja) | 2015-10-21 |
Family
ID=43298558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514183A Expired - Fee Related JP5797191B2 (ja) | 2009-06-05 | 2010-06-04 | 免疫調節ペプチドおよびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8450285B2 (enExample) |
| EP (1) | EP2437772B1 (enExample) |
| JP (1) | JP5797191B2 (enExample) |
| CN (1) | CN102803500B (enExample) |
| AU (1) | AU2010256445B2 (enExample) |
| CA (1) | CA2764164A1 (enExample) |
| MX (1) | MX2011012875A (enExample) |
| NZ (1) | NZ596780A (enExample) |
| WO (1) | WO2010141845A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2437772B1 (en) | 2009-06-05 | 2017-12-06 | 13Therapeutics, Inc. | Immunoregulatory peptides and methods of use |
| US8580748B2 (en) | 2011-04-06 | 2013-11-12 | 13Therapeutics, Inc. | Peptides for the treatment of hearing |
| TWI609889B (zh) * | 2016-05-11 | 2018-01-01 | 偉喬生醫股份有限公司 | 提升蛋白質遞送至細胞內之效率的蛋白標籤及方法 |
| KR101943978B1 (ko) * | 2017-12-28 | 2019-01-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
| CN109456390B (zh) * | 2018-12-27 | 2021-11-16 | 西华师范大学 | 一种人工合成多肽h-473及其应用 |
| KR20230100729A (ko) * | 2020-10-30 | 2023-07-05 | 푸단 유니버시티 | 면역반응 조절 또는 항종양 약물 제조에 있어 itpripl1 조절제의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1979000515A1 (en) | 1978-01-16 | 1979-08-09 | Univ Boston | Method of effecting cellular uptake of molecules |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| DK0554284T3 (da) | 1990-10-24 | 1997-01-06 | Allelix Biopharma | Peptid-baserede hæmmere af Hiv-replikation |
| CA2094658A1 (en) | 1992-04-23 | 1993-10-24 | Martin Sumner-Smith | Intracellular delivery of biochemical agents |
| EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| AU729643B2 (en) | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| US6228344B1 (en) | 1997-03-13 | 2001-05-08 | Mallinckrodt Inc. | Method of measuring physiological function |
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6589503B1 (en) * | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6093417A (en) | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6835713B2 (en) * | 2001-02-16 | 2004-12-28 | University Of Pittsburgh | Virus derived antimicrobial peptides |
| EP1385872A4 (en) * | 2001-05-11 | 2004-12-15 | Res Dev Foundation | NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS |
| EP1412390A2 (en) * | 2001-07-26 | 2004-04-28 | Tanox, Inc. | Agents that activate or inhibit toll-like receptor 9 |
| JP2006509724A (ja) * | 2002-08-01 | 2006-03-23 | ワイス | 炎症及びアポトーシスに関係する方法及び試薬 |
| AU2003264836A1 (en) * | 2002-09-05 | 2004-03-29 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Orthopoxvirus vectors, genes and products thereof |
| CA2520655A1 (en) | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US7192930B2 (en) * | 2004-07-12 | 2007-03-20 | U.S. Department Of Veterans Affairs | Method and peptide for regulating cellular activity |
| TW200719884A (en) | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
| AU2007233116B2 (en) * | 2006-03-30 | 2013-05-09 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| US20080039395A1 (en) | 2006-08-07 | 2008-02-14 | United States Government As Represented By The Department Of Veterans Affairs | Methods for treating septic shock |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US8722052B2 (en) * | 2008-11-17 | 2014-05-13 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Vaccinia virus protein A46 peptide and use thereof |
| EP2437772B1 (en) | 2009-06-05 | 2017-12-06 | 13Therapeutics, Inc. | Immunoregulatory peptides and methods of use |
| US8580748B2 (en) | 2011-04-06 | 2013-11-12 | 13Therapeutics, Inc. | Peptides for the treatment of hearing |
-
2010
- 2010-06-04 EP EP10784168.6A patent/EP2437772B1/en not_active Not-in-force
- 2010-06-04 WO PCT/US2010/037443 patent/WO2010141845A2/en not_active Ceased
- 2010-06-04 MX MX2011012875A patent/MX2011012875A/es active IP Right Grant
- 2010-06-04 AU AU2010256445A patent/AU2010256445B2/en not_active Ceased
- 2010-06-04 CA CA2764164A patent/CA2764164A1/en not_active Abandoned
- 2010-06-04 CN CN201080030313.1A patent/CN102803500B/zh not_active Expired - Fee Related
- 2010-06-04 NZ NZ596780A patent/NZ596780A/xx not_active IP Right Cessation
- 2010-06-04 US US12/794,185 patent/US8450285B2/en active Active
- 2010-06-04 JP JP2012514183A patent/JP5797191B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-29 US US13/753,141 patent/US9150617B2/en not_active Expired - Fee Related
- 2013-01-29 US US13/753,106 patent/US9150616B2/en not_active Expired - Fee Related
- 2013-01-29 US US13/752,969 patent/US9187530B2/en not_active Expired - Fee Related
-
2015
- 2015-10-06 US US14/876,298 patent/US9974853B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Recovery and regeneration after spinal cord injury: a review and summary of recent literature | |
| CN103841987B (zh) | 退行性关节病的治疗 | |
| ES2600616T3 (es) | Antagonistas del receptor de la interleucina-1 | |
| JPWO2019156137A5 (enExample) | ||
| TW201018471A (en) | Multiple exon skipping compositions for DMD | |
| JP6158713B2 (ja) | ヒトラクトフェリン由来ペプチド及びその使用 | |
| JP2010533705A5 (enExample) | ||
| US20250235489A1 (en) | Ammonia oxidizing microorganisms for use and delivery to the intranasal system | |
| CN117157049A (zh) | Atp合酶抑制剂-化妆品和治疗用途 | |
| ATE399562T1 (de) | Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen | |
| JP2023126760A (ja) | 抗炎症剤 | |
| JP2026506026A (ja) | 新規多機能オリゴペプチド | |
| US20250205290A1 (en) | Use and delivery of ammonia oxidizing microorganisms for treatment of neurodegenerative disorders | |
| JP5797191B2 (ja) | 免疫調節ペプチドおよびその使用 | |
| US20250325763A1 (en) | Devices for storage and delivery of nonpathogenic microorganisms | |
| JP2009542609A5 (enExample) | ||
| JP6573294B2 (ja) | 炎症性疾患の予防または治療用ペプチド及びその用途 | |
| Kumar et al. | Recent patent advances for neurodegenerative disorders and its treatment | |
| WO2018231994A1 (en) | Ammonia oxidizing microorganisms for dispersing biofilms | |
| ES2554332T3 (es) | Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40 | |
| US20230201274A1 (en) | Shelf- stable ammonia oxidizing microorganism preparations | |
| RU2013139704A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера | |
| WO2001093863A3 (en) | Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression | |
| BR112020008350A2 (pt) | moduladores agonísticos de receptor de glicocorticóide seletivos (segrams) não esteroidais e usos dos mesmos | |
| US20240226192A1 (en) | Ammonia oxidizing microorganisms for the treatment of headaches |